115 related articles for article (PubMed ID: 38522641)
1. Fatostatin promotes anti-tumor immunity by reducing SREBP2 mediated cholesterol metabolism in tumor-infiltrating T lymphocytes.
Zhu L; Shi Y; Feng Z; Yuan D; Guo S; Wang Y; Shen H; Li Y; Yan F; Wang Y
Eur J Pharmacol; 2024 May; 971():176519. PubMed ID: 38522641
[TBL] [Abstract][Full Text] [Related]
2. Fatostatin Inhibits Cancer Cell Proliferation by Affecting Mitotic Microtubule Spindle Assembly and Cell Division.
Gholkar AA; Cheung K; Williams KJ; Lo YC; Hamideh SA; Nnebe C; Khuu C; Bensinger SJ; Torres JZ
J Biol Chem; 2016 Aug; 291(33):17001-8. PubMed ID: 27378817
[TBL] [Abstract][Full Text] [Related]
3. Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner.
Shao W; Machamer CE; Espenshade PJ
J Lipid Res; 2016 Aug; 57(8):1564-73. PubMed ID: 27324795
[TBL] [Abstract][Full Text] [Related]
4. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling.
Li X; Chen YT; Hu P; Huang WC
Mol Cancer Ther; 2014 Apr; 13(4):855-66. PubMed ID: 24493696
[TBL] [Abstract][Full Text] [Related]
5. Fatostatin inhibits the development of endometrial carcinoma in endometrial carcinoma cells and a xenograft model by targeting lipid metabolism.
Yao L; Chen S; Li W
Arch Biochem Biophys; 2020 May; 684():108327. PubMed ID: 32142890
[TBL] [Abstract][Full Text] [Related]
6. Fatostatin inhibits SREBP2-mediated cholesterol uptake via LDLR against selective estrogen receptor α modulator-induced hepatic lipid accumulation.
Li M; Lu Q; Zhu Y; Fan X; Zhao W; Zhang L; Jiang Z; Yu Q
Chem Biol Interact; 2022 Sep; 365():110091. PubMed ID: 35944649
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol Induces CD8
Ma X; Bi E; Lu Y; Su P; Huang C; Liu L; Wang Q; Yang M; Kalady MF; Qian J; Zhang A; Gupte AA; Hamilton DJ; Zheng C; Yi Q
Cell Metab; 2019 Jul; 30(1):143-156.e5. PubMed ID: 31031094
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
9. Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma.
Gao S; Shi Z; Li X; Li W; Wang Y; Liu Z; Jiang J
Oncol Rep; 2018 Apr; 39(4):1919-1929. PubMed ID: 29436682
[TBL] [Abstract][Full Text] [Related]
10. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
[TBL] [Abstract][Full Text] [Related]
11. Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer.
Liu Y; Zhang N; Zhang H; Wang L; Duan Y; Wang X; Chen T; Liang Y; Li Y; Song X; Li C; Han D; Chen B; Zhao W; Yang Q
Drug Des Devel Ther; 2020; 14():3535-3545. PubMed ID: 32921987
[TBL] [Abstract][Full Text] [Related]
12. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
13. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP.
Kamisuki S; Mao Q; Abu-Elheiga L; Gu Z; Kugimiya A; Kwon Y; Shinohara T; Kawazoe Y; Sato S; Asakura K; Choo HY; Sakai J; Wakil SJ; Uesugi M
Chem Biol; 2009 Aug; 16(8):882-92. PubMed ID: 19716478
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
15. Fatostatin ameliorates inflammation without affecting cell viability.
Ma S; Murakami K; Tanaka K; Hashimoto M; Tanaka M; Kitagori K; Akizuki S; Nakashima R; Yoshifuji H; Ohmura K; Morinobu A; Mimori T
FEBS Open Bio; 2022 Mar; 12(3):594-604. PubMed ID: 35015380
[TBL] [Abstract][Full Text] [Related]
16. Metformin treatment prevents SREBP2-mediated cholesterol uptake and improves lipid homeostasis during oxidative stress-induced atherosclerosis.
Gopoju R; Panangipalli S; Kotamraju S
Free Radic Biol Med; 2018 Apr; 118():85-97. PubMed ID: 29499335
[TBL] [Abstract][Full Text] [Related]
17. Disruption of Cancer Metabolic SREBP1/miR-142-5p Suppresses Epithelial-Mesenchymal Transition and Stemness in Esophageal Carcinoma.
Huang CM; Huang CS; Hsu TN; Huang MS; Fong IH; Lee WH; Liu SC
Cells; 2019 Dec; 9(1):. PubMed ID: 31861383
[No Abstract] [Full Text] [Related]
18. Inhibition of SREBP With Fatostatin Does Not Attenuate Early Diabetic Nephropathy in Male Mice.
Van Krieken R; Marway M; Parthasarathy P; Mehta N; Ingram AJ; Gao B; Krepinsky JC
Endocrinology; 2018 Mar; 159(3):1479-1495. PubMed ID: 29420703
[TBL] [Abstract][Full Text] [Related]
19. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8
Liu C; Chikina M; Deshpande R; Menk AV; Wang T; Tabib T; Brunazzi EA; Vignali KM; Sun M; Stolz DB; Lafyatis RA; Chen W; Delgoffe GM; Workman CJ; Wendell SG; Vignali DAA
Immunity; 2019 Aug; 51(2):381-397.e6. PubMed ID: 31350177
[TBL] [Abstract][Full Text] [Related]
20. Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8
Hu C; Qiao W; Li X; Ning ZK; Liu J; Dalangood S; Li H; Yu X; Zong Z; Wen Z; Gui J
Cell Metab; 2024 Mar; 36(3):630-647.e8. PubMed ID: 38309268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
